![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia, University of Perugia, Perugia, Italy (E.D., A.Me., L.S., B.R., S.O., E.A., A.Mo., S.F.); Dipartimento di Farmacologia Sperimentale, University of Naples, Napoli, Italy (G.C., F.R.); and Mucosal Inflammation Research Group, University of Calgary, Calgary, Alberta, Canada (J.L.W.)
Hydrogen sulfide (H2S) functions as a neuromodulator, but
whether it modulates visceral perception and pain is unknown. Cystathionine
β-synthase (CBS) and cystathionine-
-lyase (CSE) mediate enzymatic
generation of H2S in mammalian cells. Here we have investigated the
role of H2S in modulating nociception to colorectal distension, a
model that mimics some features of the irritable bowel syndrome. Four graded
(0.4–1.6 ml of water) colorectal distensions (CRDs) were produced in
conscious rats (healthy and postcolitic), and rectal nociception was assessed
by measuring the behavioral response during CRD. Healthy rats were
administered with sodium hydrogen sulfide (NaHS) (as a source of
H2S), L-cysteine, or vehicle. In a second model, we
investigated nociception to CRD in rats recovering from a chemically induced
acute colitis. We found that CBS and CSE are expressed in the colon and spinal
cord. Treating rats with NaHS resulted in a dose-dependent attenuation of
CRD-induced nociception with the maximal effect at 60 µmol/kg (p
< 0.05). Administration of L-cysteine, a CSE/CBS substrate,
reduced rectal sensitivity to CRD (p < 0.05). NaHS-induced
antinociception was reversed by glibenclamide, a ATP-sensitive K+
(KATP) channel inhibitor, and
N
-nitro-L-arginine methyl ester
hydrochloride (L-NAME), a nitric-oxide (NO) synthase inhibitor. The
antinociceptive effect of NaHS was maintained during the resolution of colon
inflammation induced by intrarectal administration of a chemical irritant. In
summary, these data show that H2S inhibits nociception induced by
CRD in both healthy and postcolitic rats. This effect is mediated by
KATP channels and NO. H2S-releasing drugs might be
beneficial in treating painful intestinal disorders.
Address correspondence to: Dr. Eleonora Distrutti, University of Perugia, Clinica di Gastroenterologia, Policlinico Monteluce, Via Enrico Dal Pozzo, 06122 Perugia, Italy. E-mail: eleonoradistrutti{at}katamail.com
This article has been cited by other articles:
![]() |
M. Schemann and D. Grundy Role of hydrogen sulfide in visceral nociception Gut, June 1, 2009; 58(6): 744 - 747. [Full Text] [PDF] |
||||
![]() |
M Matsunami, T Tarui, K Mitani, K Nagasawa, O Fukushima, K Okubo, S Yoshida, M Takemura, and A Kawabata Luminal hydrogen sulfide plays a pronociceptive role in mouse colon Gut, June 1, 2009; 58(6): 751 - 761. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Nishimura, O Fukushima, H Ishikura, T Takahashi, M Matsunami, T Tsujiuchi, F Sekiguchi, M Naruse, Y Kamanaka, and A Kawabata Hydrogen sulfide as a novel mediator for pancreatic pain in rodents Gut, June 1, 2009; 58(6): 762 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Andruski, D.-M. McCafferty, T. Ignacy, B. Millen, and J. J. McDougall Leukocyte trafficking and pain behavioral responses to a hydrogen sulfide donor in acute monoarthritis Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2008; 295(3): R814 - R820. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. C. Yong, S. W. Lee, C. S. Foo, K. L. Neo, X. Chen, and J.-S. Bian Endogenous hydrogen sulphide mediates the cardioprotection induced by ischemic postconditioning Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1330 - H1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Distrutti, L. Sediari, A. Mencarelli, B. Renga, S. Orlandi, G. Russo, G. Caliendo, V. Santagada, G. Cirino, J. L. Wallace, et al. 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 447 - 458. [Abstract] [Full Text] [PDF] |
||||